Rob J. Van Klaveren, M cialis and viagra .D., Ph.D., Matthijs Oudkerk, M.D., Ph.D., Mathias Prokop, M.D., Ph.D., Ernst T. Scholten, M.D., Kristiaan Nackaerts, M.D., Ph.D., Rene Vernhout, M.Sc., Carola A. Van Iersel, M.Sc., Karien A.M. Van den Bergh, M.Sc., Susan van ‘t Westeinde, M.D., Carlijn van der Aalst, M.Sc., Erik Thunnissen, M.D., Ph.D., Dong Ming Xu, M.D., Ph.D., Ying Wang, M.D., Yingru Zhao, M.D., Hester A. Gietema, M.D., Ph.D., Bart-Jan de Hoop, M.D., Harry J.M. Groen, M.D., Ph.D., Geertruida H.
After vaccination with seasonal vaccine, the GMT of antibodies against 2009 H1N1 didn’t increase by a factor of four or more in any of the 55 kids who received trivalent inactivated vaccine, although a robust response to seasonal vaccine strains was detected in 67 to 100 percent of the children. Furthermore, no seroconversion to antibodies against 2009 H1N1 was detected in any of the 24 children between the ages of six months to 9 years who were vaccinated with live attenuated influenza vaccine . However, only 7 of 24 recipients of the live attenuated vaccine had an increase by a factor of four or even more in the antibody titer against the seasonal vaccine strain, and all the young children had a lower postvaccination GMT, in comparison with recipients of the inactivated vaccine, as reported previously.14 Vaccination of 344 adults with inactivated seasonal vaccine resulted in seroconversion against the seasonal H1N1 vaccine stress in 65 of 83 adults between the age groups of 18 and 40 years , in 111 of 148 of those between the age range of 18 and 64 years , and in 9 of 49 and 34 of 63 of these 60 years or older, depending on the year .